Among small-molecule drugs, upadacitinib and deucravacitinib demonstrate the best efficacy for treatment of psoriatic ...

Skyrizi (risankizumab) was previously already cleared by the FDA for adults with moderately to severely active Crohn's disease, active psoriatic arthritis, and moderate to severe plaque psoriasis.

Skyrizi was the top Rx and over-the-counter (OTC) pharma brand advertising on TV in 2024, according to data released by iSpot.tv on Thursday afternoon. AbbVie’s psoriasis, ulcerative colitis, Crohn’s ...

AbbVie (ABBV), a large drug maker, is jumping 8% after the company provided significantly higher-than-expected 2025 earnings ...

Hispanic and non-White patients with psoriatic arthritis (PsA) had higher tender joint counts and greater disease severity, ...

Its key drugs include Humira for treating rheumatoid arthritis, psoriasis, Crohn’s disease and other conditions, and Skyrizi for treating plaque psoriasis, psoriatic arthritis, Crohn’s disease ...

AbbVie's strong earnings and growth projections make it a solid buy for 2025, with no major patent expirations until 2030. Learn more on ABBV stock here.